Symbiotec Pharmalab Ltd (SYMPHA)

CMP: Rs. 1200 | Target: Rs. 1540 (28%) | Target Period: 12 month | BUY

October 1, 2026

Fermentation at the fore- Moving into high-value extensions...

About the company- Madhya Pradesh (MP) based Symbiotec Pharmalab Limited (SPL) is an API company with focus on corticosteroid (man-made drugs that copy natural cortisol) and steroidal-hormone APIs with a global leadership. It manufactures these products using fermentation and multi-step complex chemical reactions.

- The company has two API manufacturing facilities the Rau Facility, and the Pithampur Facility. Further, the company has commissioned two additional manufacturing facilities in Ujjain and Mhow.
- Capacity: Chemical Synthesis - ~585 MT, Fermentation – 700 KL, Double Chamber Vials – 20 million units per annum.

Investment Rationale

- **Long standing leadership in global corticosteroid and steroidal hormone APIs:** Symbiotec enjoys a strong global leadership position in corticosteroid and steroidal hormone APIs, with a global volume market share of 38.2% and 23.8%, respectively. Its portfolio comprises of ~60 products across sterile and non-sterile formats, catering to a diversified customer base of 200+ clients across 40+ countries, including 150+ export customers. Strong customer stickiness is reflected in an average relationship tenure of nearly 10 years with its top 10 customers. The corticosteroid and steroidal hormone APIs segment is expected to grow at ~8–10% CAGR during FY26-FY29E to be driven by a stable base business growth and traction from new products such as Vegan D3, Docosahexaenoic Acid (dietary supplement), UDCA (Gastrointestinal medication) and Premarin (conjugated estrogens). The segment remains a stable cash generator for new ventures in future.
- **Significant investments to extend the current platform towards complex injectables and CDMO:** SPL has been on a capex drive over the past 3–4 years and has invested ~₹1,000+ crore in the new businesses, including ₹376 crore towards Complex Injectables and ₹584 crore towards CDMO. In CDMO, the company has multiple contracts with Take-or-Pay arrangements, providing greater revenue visibility, and in Complex Injectables, which represents a natural forward integration of its existing API capabilities, the company is developing double-chamber vial products and has already partnered for the commercialisation of its first two products, with milestones expected in FY27E and commercial revenues from FY28E. We believe these businesses can be value-accretive over the long term and support a structural improvement in the company's margin profile from ~27% currently to ~32% by FY29E, alongside an estimated revenue CAGR of ~23% over FY26–29E.

Rating and Target Price: we initiate **Buy** on SPL with a price target of **₹ 1540** (valuing at 19x FY29E EBITDA of ₹542.4 crore). We believe the company has the required wherewithal to transition from a legacy API to complex APIs / CDMO model.

Particulars

Particular	Amount
Market Capitalisation	₹ 7518 crore
Debt (FY26)	₹ 391 crore
Cash (FY26)	₹ 10 crore
EV (Rs crore)	₹ 7899 crore
52-week H/L (₹)	1246/934
Equity capita	₹ 12.5 crore
Face value	₹ 2

Shareholding pattern (%)

Particulars	Sep-26
Promoters	33.3
FII	21.1
DII	27.5
Others	18.1

Price Chart



Key risks

- Delay in ramping up of new business verticals
- Regulatory and compliance risk

Research Analyst

Siddhant Khandekar
Siddhant.khandekar@icicisecurities.com

Shubh Mehta
Shubh.mehta@icicisecurities.com

Vedant Nilekar
Vedant.nilekar@icicisecurities.com

Conviction Pick

ICICI Securities – Retail Equity Research

Key Financial Summary

₹ Crore	FY23	FY24	FY25	FY26	CAGR FY23-26 (%)	FY27E	FY28E	FY29E	CAGR FY26-29E (%)
Revenues	566.5	716.2	751.6	869.1	15.3	1016.4	1330.0	1628.3	23.3
EBITDA	68.9	171.3	201.8	237.9	51.2	287.7	427.2	542.4	31.6
EBITDA Margins (%)	12.2	23.9	26.9	27.4		28.3	32.1	33.3	
Net Profit	24.6	101.4	96.9	109.9	64.8	140.2	213.0	276.7	36.0
EPS (Adjusted)	3.7	15.6	15.1	18.5		21.8	33.1	43.1	
PE (x)	328.3	77.1	79.7	70.2		55.0	36.2	27.9	
EV to EBITDA (x)	115.1	46.4	40.8	34.0		28.0	19.0	14.8	
RoCE (%)	5.4	14.0	11.6	11.9		10.8	15.5	17.8	
RoE (%)	3.8	14.0	11.8	10.3		9.7	12.8	14.3	

Source: Company, ICICI Direct Research

Company Background

MP based Symbiotec Pharmalab Limited (SPL) is an API company with focus on corticosteroid (man-made drugs that copy natural cortisol) and steroidal-hormone APIs with a global leadership. It manufactures these products using fermentation and multi-step complex chemical reactions.

SPL has established capabilities across three platforms:

- **organic chemistry**, including flow chemistry, hydrogenation, and photochemistry.
- **biotechnology**, including biosynthesis and biotransformation, and recombinant biologics, including Glucagon-like Peptide-1 and Insulins.
- forward integration into **complex injectables** including double-chamber vials, double-chamber bags and double-chamber syringes.

The company owns two operational industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes, fermentation capacity of 300 kilolitres. It has also commissioned two additional manufacturing facilities at Ujjain and Mhow leading to an aggregate maximum chemical synthesis capacity of 584.67 MT, maximum fermentation capacity of 700 KL, and complex injectables capacity of 20 million vials per annum, enabling it to function as a vertically integrated 'microbe-to-pharmacy' and 'farm-to-pharmacy' platform with cost-efficient operations.

Exhibit 1: Manufacturing infrastructure



Source: RHP, ICICI Direct Research

Its biotechnology facilities are equipped with fermenters of 5 KL, 35 KL and 100 KL, providing them flexibility in the scale of operations. Further, it is in process of expanding their biologics capacity by adding dedicated 14 KL (comprising two reactors of 7 KL each) fermentation capacity for biologics manufacturing in Ujjain, Madhya Pradesh.

Exhibit 2: SPL's Timeline



Source: Company RHP, ICICI Direct Research

SPL capabilities are enabled by conversion of commodity plant-based derivative inputs (farm/ microbe-to pharmacy approach) and work with diverse microbial strains such as bacteria, fungi, yeast and algae to convert into high value steroid and hormonal pre-cursors. This supports backward integration and allows the company

to make strategic, cost-effective 'make versus buy' decisions for key starting materials for over 80% of their products by revenue, thereby reducing external dependence for sourcing intermediates from other geographies. SPL is among the few backward-integrated Indian and global manufacturers capable of producing in-house corticosteroid and hormone precursors.

Exhibit 3: Integrated Pharma to pharmacy approach



Source: Company, ICICI Direct Research

Company's fermentation capabilities span into four distinct modalities:

- Biotransformation of soy-derived sterols to corticosteroid and hormone pre-cursors, with in-house control over each step, from raw material to final API production
- Classical fermentation for pipeline APIs, including anti-infectives, anti-fungal, immunosuppressants, enzymes and anti-parasitic.
- Recombinant protein expression technologies to address newer pharmaceutical categories like GLP-1 and Insulins; and
- Precision fermentation and synthetic biology for nutraceuticals and food applications, including alternate proteins, and other industrial biotechnological products.

SPL through its three business verticals supplies products to over 200 customers in over 40 countries, including leading generic and specialty pharmaceutical companies in the United States, Europe, and Asia – (i) API products, (ii) CDMO services, and (iii) complex injectables.

Exhibit 4: Business vertical classification with platforms



Source: RHP, ICICI Direct Research

Investment Rationale

API business- banking on steroidal expertise and fermentation capabilities-

API business is a matured business for SPL. The portfolio comprises of 1) corticosteroid APIs (~60% of API sales), 2) steroidal-hormone APIs (40% of API sales).

The company currently owns two operational industrial scale API manufacturing facilities at Rau and Pithampur (both near Indore in MP) with a maximum chemical synthesis capacity of 584.67 metric tonnes and fermentation capacity of 300 kilolitres.

The Rau plant handles steroidal APIs in both sterile and non-sterile formats and has a maximum chemical synthesis capacity of 92 MT. Similarly, the Pithampur plant, has a maximum chemical synthesis capacity of 492.67 MT and fermentation capacity of 300 KL. It houses four fermenters of 5 KL each dedicated to low-volume, high-value APIs, as well as eight fermenters of 35 KL each for medium-volume, medium-value APIs.

The key starting material is a molecule called phytosterol, which is a plant-based steroid. This product is a byproduct derived from the process of oil extraction from soybean. The company procures the same from large food processing companies such as Cargill Inc. The first few stages from phytosterol to the final product pass through the fermentation process. The intermediate derived from the fermentation is further processed through the chemical synthesis to manufacture the ultimate finished product (corticosteroid / steroidal hormone). Which is why the existing Pithampur plant has both the fermentation and chemical synthesis capabilities.

However, the despite having backward integrated model (90-95% backward integration), the company resorts to importing of 45-50% of the requirements from China to maintain the unit economics.

Exhibit 5: Manufacturing Process



Source: Company RHP, ICICI Direct Research

Global formulations market for corticosteroid and steroidal-hormone APIs is ~US$ 10 billion whereas API market is ~US$ 1 billion, as per management estimates. With US$ 100 million bandwidth, SPL holds ~10% market share, globally. It's among the top 5 players with two competitors from China and two from Europe.

In volume terms, SPL has a market share of ~38% in corticosteroids and ~24% in steroidal hormones (excluding androstenedione and hydroxyprogesterone caproate), respectively. It is the only Indian and global company to have a presence across the top 10 corticosteroid and steroidal-hormone APIs.

The demand for corticosteroid piggybacks on rising prevalence of inflammatory and autoimmune diseases globally, including rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, and inflammatory bowel disease among others. Studies have shown that up to 10% of individuals in industrialized countries suffer from at least one autoimmune condition, which is contributing to the growing need for corticosteroid-based treatments. The steroidal-hormone APIs market is expanding on the back of rising demand for reproductive health, metabolic disorder,

and hormone replacement therapies. Advancements in drug delivery platforms, such as the development of aerosols and double chamber systems, along with innovation in novel corticosteroid derivatives, are expected to open new avenues for application and commercialisation of corticosteroid-based treatments.

Exhibit 6: Symbiotec position in global API market for select products

Product	Volume Growth Rate for Symbiotec (FY24-FY26), %	Symbiotec Volume Market Share (FY-24)	Symbiotec Volume Market Share (Fiscal 2025)	Symbiotec Volume Market Share (Fiscal 2026)
Progesterone	0.0	24.2%	26.1%	21.2%
Prednisolone	-0.2	7.4%	13.0%	4.9%
Hydrocortisone	0.1	73.6%	78.9%	80.1%
Betamethasone	-0.1	48.2%	39.2%	33.4%
Testosterone	0.5	41.6%	70.4%	76.4%
Methylprednisolone	0.2	55.0%	50.6%	76.0%
Clobetasol Propionate	0.1	39.9%	38.5%	50.0%
Androstenedione	0.3	2.4%	4.9%	3.9%
Hydroxyprogesterone Caproate	1.4	NA	NA	NA

Source: Company RHP, ICICI Direct Research

The portfolio comprises of 60+ corticosteroid and steroidal-hormone APIs, spanning both sterile and nonsterile formats. This broader product bandwidth covers almost 90% of the corticosteroid and steroidal-hormone API products globally.

SPL, till FY26 had 43 drug master files registered with the USFDA and 23 certificates of suitability from the European Directorate.

As most of the products in the API portfolio are matured products, growth is mainly driven by volumes and incremental market share. Compared to corticosteroids, steroidal hormones have better growth prospects. Growth for corticosteroids is expected to be around 4-5% whereas for steroidal hormones it could be around 7-8% due to growing instances of hormonal imbalances (the segment is experiencing significant M&A activities globally).

Future expansion to target niche and complex products

In addition to the legacy APIs, SPL is looking to expanding product base in classical fermentation-based APIs such as Mupirocin (anti-bacterial) and Serratiopeptidase (pain management), among others, as well as speciality ingredients such as Algal based Docosa Hexanoic Acid, a dietary supplement.

Another future product is specialty ingredients for vegan based vitamin D3. This is a photochemistry-based product. Vegan based vitamin D3 is a niche market valued at US$ 600 million and is growing at ~10% on the back of growing demand for cruelty-free vitamin D alternatives across health-conscious consumers, vegan lifestyle adherents, and nutritionally aware demographics. As per management, this segment remains attractive with few competitors. The company is putting a dedicated capacity for the same which is expected to be functional in FY28.

The company is also developing a generic alternative to Premarin (conjugated equine estrogens), which used predominantly in hormone replacement therapies (HRT) and prevention of osteoporosis. The product is currently in validation stage. The global conjugated estrogen market was valued at US$ 380 million in 2024. Despite the expiry of market exclusivity, Premarin has only one generic substitute, largely due to the complexity of its raw material, which is derived from the urine of pregnant mares, and the challenges associated with replicating its hormonal composition. Considering the timeline of API development phase, followed by the formulation development and ANDA filing, this could be a meaningful opportunity by FY29.

We expect API to grow at a CAGR of ~8% during FY26-29E to ₹1061.6 crore to be driven by steady growth in corticosteroid (matured portfolio) and steroidal hormones (lifestyle related and slightly higher traction). We expect the new product introductions discussed supra are likely to provide more traction from the exit year.

Exhibit 7: API business to grow at 8.3% CAGR during FY26-28E



Source: Company, ICICI Direct Research

Long term plans in the CDMO space- to partner with global companies for difficult-to-execute projects

SPL houses the CDMO business under its subsidiary Symbiotec Zenfold Private Limited where it has signed multiple contracts to develop and supply complex biotechnology products to specialty pharmaceutical and food/ nutraceutical companies worldwide. It has recently commissioned 400 KL fermentation capacity at Ujjain which would be primarily dedicated for servicing its CDMO business.

Under the CDMO business SPL has collaborated with several global and Indian Pharma companies with a take or pay arrangement (clause applicable with most of the partners. The contracts include-

- Insulin drug substance supply for a period of five years with a take-or-pay commercial arrangement.
- Classical fermentation-based APIs supply for a period of ten years with a take-or-pay commercial arrangement.
- Within non-pharmaceutical CDMO services, SPL have entered into a ten-year take-or-pay contract with a US company for the supply of an alternate protein product.
- Within non-pharmaceutical CDMO services, SPL have entered into a term sheet with a European company for the supply of an alternate protein product with a scale ranging from 600 KL initially and ramping to 1,600 KL based on need.
- Company have signed term sheets with a company to offer fermentation-based CDMO services for nutraceuticals, alternative proteins and other industrial biotechnology products.

Outsourcing to fermentation CDMOs is gaining momentum across pharmaceuticals, food, nutraceuticals, agriculture, and specialty chemicals as companies aim to bypass heavy capital investment, accelerate scale-up, and leverage specialized microbial and process engineering expertise.

India structurally offers advantages for CDMO services, including 30-50% lower setup and commissioning costs, low operating cost of utilities, labour and compliance, which ensures affordable raw material access and a growing ecosystem. The growth in the segment is mainly driven by biologics while Alternate Protein has also started witnessing traction where SPL aims to capture material opportunity.

Exhibit 8: Global Pharma and Non-pharma Fermentation CDMO, 2025-2030F

Type of Market	Market Size in 2025 (USD Billion)	Market Size in 2030F (USD Billion)	CAGR 2025 - 2030F
Small Molecule Pharma	7.8	11.2	7.50%
Biologics (Pharma)	11.1	24	16.70%
Specialty Ingredients	31	47.5	8.90%
Alternate Proteins	2.7	4.2	9.20%

Source: Company RHP, ICICI Direct Research

Going forward, SPL plans to deepen their engagement with existing CDMO clients while actively pursuing new commercial opportunities in key international markets, including the United States, the European Union, and other markets.

We expect the CDMO business to gain traction from Europe-based alternate protein contracts in FY27, followed by insulin and US-based alternate protein contracts by FY28. With these contracts ramping up, we estimate the segment to scale to ~₹360 crore in revenue by FY29.

Exhibit 9: CDMO revenues to scale to ~₹360 crore by FY29E



Source: Company, ICICI Direct Research

Commercializing complex injectables through differentiated drug device combinations

Company have strategically invested in forward integration to complement their API and fermentation strengths with capabilities in technically complex injectables.

SPL's complex injectables platform is cantered on double chamber vials, double chamber bags, and double chamber syringes. They are one of the first generics companies globally to successfully develop DCV through backward integration, by relying on in-house materials and not imports, for **Methylprednisolone Sodium Succinate injection and Hydrocortisone Sodium Succinate** with their platform scaled for commercial execution.

Double chamber injectable drug-device combinations command a substantial 20–50% price premium over conventional injectables, particularly in biologics and specialty therapies. This premium is likely to be attributable to their advantages, including enhanced drug stability, dosing accuracy, improved ease of use, reduced contamination risk, and significant reductions in wastage—which benefit both patients and providers.

Exhibit 10: Double Chamber Vials

Source: Company RHP, ICICI Direct Research

The market for DCVs is dominated by innovators, with 65% - 70% of the market held by innovators and there are inherent access barriers primarily due to the requirement of advanced manufacturing capabilities, huge capex, strong R&D, strong intellectual property positions, and robust regulatory compliance.

Commercialisation of Symbiotec first two DCV products, Methylprednisolone Sodium Succinate injection and Hydrocortisone Sodium Succinate, is expected in FY27/28. With a market size in the US of ~US$ 300 million, 90% market share is currently with innovator Pfizer while only 10% is spread across more than 5 generic players. SPL has already partnered with global specialty pharmaceutical companies to commercialise one of its two DCV product while initial trench of milestone income

is expected by end of this fiscal and commercialization of second product is also expected by end of FY28.

In addition to the initial two products, SPL is also developing additional DCV products under the 505(b)(2) regulatory pathway with TAM of ~US$ 890 million in 2025 globally we believe it to be material opportunity for SPL in medium to long term.

We estimate company to have milestone income of ~₹100 crore in FY27E (based on management guidance to cover full year opex drag) from the commercialization of first DCV product and with other launches planned in the coming fiscals, the segment is poised to scale to ~₹208 crore by FY29E.

Exhibit 11: Complex Injectable revenues to scale to ~₹208 crore by FY29E



Source: Company, ICICI Direct Research

Exhibit 12: Overview of the overall potential

	API Products	CDMO Services	Complex Injectables
Select Successes	Conjugated Estrogen	Fermentation-based Alternate Proteins	Double Chamber Vials (DCV)
Key Highlight	One of the few companies globally to successfully develop the complex API [2]	One of India's largest industrial-scale fermentation capacities	One of the first generics globally to develop DCV through backward integration [3]
Symbiotec's Right to Win	Addressing the complexity of supply chain; Farm to pharmacy; Distribution partnership	Successfully demonstrated technology at 100 KL scale; Multi-scale flexible mfg.; JV agreement in place	In-house API supply; Distribution partnership; High entry barriers
TAM[1]	USD 220 mn (Formulation TAM)	USD 2.7 bn	USD 1.8 bn
Revenue Streams	Product Sale; Milestone Payments; Profit / Revenue Share[4]	Service Income; Profit / Revenue Share	Product Sales; Milestone Payments; Profit / Revenue Share
Future Potential Offerings	Synthetic biology based Proprietary APIs	Food, nutraceuticals, biologics & industrial biotech CDMO	Double Chamber Bags, Double Chamber Syringes, Pre-Filled Syringes

Customer relationship established and revenue generated; Customer relationship established; revenue not generated

Source: Company RHP, ICICI Direct Research

Key Financial Summary

Revenues to grow at CAGR of 24% over FY26-29E...

SPL's revenue grew at a 15% CAGR over FY23–26, driven primarily by growth in its API business. With new growth segments such as CDMO, where multiple contracts are expected to commence, and Complex Injectables, with the commercialization of two DCV products, we expect revenue growth to accelerate to ~23% CAGR over FY26–29E.

Exhibit 13: Revenues to grow at 23% CAGR during FY26-29E



Source: Company, ICICI Direct Research

EBITDA margins to expand further as new business verticals ramps up...

The fermentation CDMO business typically commands an EBITDA margin of ~30–35%, while DCVs which is niche sterile segment and offers an even higher margin profile of ~35–40%. With both segments expected to contribute materially going forward, we expect the company's EBITDA margin to improve from the current ~27% to ~33% by FY29E. Quarterly margins, however, could remain volatile due to the timing of milestone payments and technology-transfer income, which may temporarily inflate reported margins.

Exhibit 14: EBITDA margins to expand further as new business segments ramp up



Source: Company, ICICI Direct Research

Return profile to further improve led by better profitability and improved utilization...

SPL's RoE and RoCE have remained muted, primarily due to the high capital deployed ahead of revenue generation. Of the estimated ₹1475+ crore cumulative gross capex (till 30th of June 2026), only ~40% is currently revenue-generating, largely comprising the API business across Steroids and Hormones.

The company has been on a capex drive over the past 3–4 years and has invested ~₹1,000+ crore in the new businesses, including ₹376 crore towards Complex

Injectables and ₹584 crore towards CDMO. These investments are expected to start contributing meaningfully to the revenues over the next 6–12 months.

As revenues ramp up from these new sources, we expect return ratios to improve materially even as the next growth phase capex kicks in. This includes ~1,600 KL fermentation capacity at the behest of European customer demand (which would be shared investment) and incremental capacities for Double Chamber Bags and Syringes. However, we expect capex intensity to moderate, with the return profile gradually improving to ~18% in the medium term. Notably, adjusted RoCE, excluding capital employed towards new businesses, currently stands at ~30%, highlighting the underlying strength of the existing business.

Exhibit 15: Return ratios to improve ahead led by better profitability...



Source: Company, ICICI Direct Research

IPO

The ₹1757 crore IPO of Symbiotec Pharmalab in Aug-26 included a fresh issue of ₹ 150 crore and OFS of ₹1757 crore, of which Rosewood Investments Capital divested ~₹988 crore, Motilal Oswal Alternates divested ~₹475 crore and the balance was by promoter. Price band for the issue was set at ₹ 938-988/share.

Post offer, promoter holding came down from 36.4% to 33.3%. PE Motilal Oswal Alternates holds ~10% stake in the company post dilution while another marquee investor such as ICICI Prudential, Valuequest joined the table. Fresh issue of ₹150 is being used for debt repayment and working capital requirements.

Peer Comparison and Valuation

With stable legacy business growth (strong global positioning in corticosteroids and steroidal hormones), a vertically integrated manufacturing platform which is expected to provide launching pad for niche and differentiated products and an ongoing growth capex, we believe SPL offers an attractive growth opportunity. Its core business benefits from low customer churn, supported by manufacturing and regulatory complexities that create high entry barriers. The company is undertaking significant expansion, with ~₹870 crore capex planned across its Ujjain and Mhow facilities, focused on niche, vertically integrated business segments, while further growth is supported by customer/partner commitments. Management aspires to achieve 3x revenues and 4x EBITDA growth over the next five years from the FY26 base. We believe Symbiotec has a long runway for growth and assign a **BUY** rating with a **target of ₹1,540**, based on 19x FY29E EBITDA.

Exhibit 16: Comparison among Indian peers

Sr. No	Company	EV (in ₹ crore)	EV/EBITDA			RoE (%)			FY26-29E CAGR		
			FY27E	FY28E	FY29E	FY27E	FY28E	FY29E	Sales	EBITDA	PAT
1	Laurus Labs	109927	45.0	37.5	29.9	21.7	21.44	21.19	19%	27%	31%
2	Concord Biotech	13760.4	29.2	22.8	18.4	15.7	18.22	19.35	21%	27%	29%
3	Symbiotec Pharmalab	7909.2	28	19.0	14.8	9.7	12.8	14.3	23%	32%	36%

Source: Bloomberg, ICICI Direct Research

Exhibit 17: Comparison of technological capabilities among Indian peers

Focus/ Company	Symbiotec	Concord Biotech	Laurus Labs	Divi's Laboratories	Cohance Lifesciences
Biosimilars/ Biologics	✓	✓	✓	✓	✓
Biomanufacturing	✓	✓	✓	✓	✓
Biotransformation/ Biocatalysis	✓	✓	✓	✓	✓
Precision Fermentation	✓	✓	✓		
Double chamber/ Drug Device Combination	✓				
Continuous Flow Chemistry	✓	✓	✓	✓	✓
Photochemistry	✓	✓	✓	✓	✓
Complex Lyophilization	✓	✓			
Synthetic Biology	✓		✓		
Chemical Synthesis	✓	✓	✓	✓	✓
Alternative Proteins	✓		✓		
Nutraceuticals	✓		✓	✓	
Enzymes (Industrial and Food applications)	✓	✓	✓		
API Capacity	584.67 metric ton		10,900 KL (total of 6 units)	API: 16,550 KL	API: Unit 1, > 520 KL Unit 2 > 140 KL
Fermentation capacity (installed)	700 KL	1,250 KL	240 KL	Do not have fermentation capability	Do not have fermentation capability
Reactor Scale	5 KL to 100 KL	5 KL to 30 KL	2 KL to 45 KL		

Source: RHP, ICICI Direct Research

Key Risk and Concerns

Ramp up in new business verticals

SPL has incurred massive capex (~₹870 crore) at its Mhow and Ujjain facilities toward new businesses, with revenues expected to commence over the next 6–18 months. Any delay in commercialization or ramp-up of DCV products at Mhow, or delays in customer offtake/contract execution for CDMO projects, could materially impact the company's growth and return profile.

Regulatory and compliance risk

The company derives significant amount of business from Regulated markets and hence its facilities are subject to periodic inspections by regulatory authorities (USFDA, EDQM, CDSCO etc.) and customers. Any manufacturing or quality control failures may subject to regulatory action and damage SPL's reputation and have an adverse effect on its business

Customer concentration risk

Symbiotec derives a substantial portion of its revenues from key customers, including large pharmaceutical companies, which rely on the company for consistent quality and timely delivery. Its top five customers contributed 43.0% of FY26 revenues, while the top ten accounted for 57.6%. Going forward, a significant portion of revenues is expected to remain contract-driven, and any termination, or loss of key contracts could adversely impact SPL's revenues and financial performance.

Financial Summary

Exhibit 18: Profit and loss statement ₹ crore

(Year-end March)	FY26	FY27E	FY28E	FY29E
Total Operating Income	869.1	1,016.4	1,330.0	1,628.3
Growth (%)	15.6	16.9	30.9	22.4
Raw Material Expenses	315.5	316.3	414.6	524.7
Gross Profit	553.7	700.1	915.3	1,103.7
Gross Profit Margins (%)	63.7	68.9	68.8	67.8
Employee Expenses	154.3	194.9	234.3	272.5
Other Expenditure	161.5	217.5	253.9	288.8
Total Operating Expenditure	631.3	728.8	902.8	1,086.0
EBITDA	**237.9**	**287.7**	**427.2**	**542.4**
Growth (%)	17.8	20.9	48.5	27.0
Interest	25.3	26.7	26.7	26.7
Depreciation	53.3	87.3	106.2	123.3
Other Income	3.1	1.6	2.1	2.5
PBT before Exceptional Items	**162.4**	**175.2**	**296.4**	**394.9**
Less: Exceptional Items	9.0	0.0	0.0	0.0
PBT after Exceptional Items	153.4	175.2	296.4	394.9
Total Tax	43.5	35.0	68.2	90.8
PAT before MI	109.9	140.2	228.2	304.1
PAT	**109.9**	**140.2**	**213.0**	**276.7**
Growth (%)	13.4	27.6	51.9	29.9
EPS (Adjusted)	**18.5**	**21.8**	**33.1**	**43.1**

Source: Company, ICICI Direct Research

Exhibit 19: Cash Flow Statement ₹ crore

(Year-end March)/ (₹ crore)	FY26	FY27E	FY28E	FY29E
Profit/(Loss) after taxation	109.9	140.2	213.0	276.7
Add: Depreciation & Amortization	53.3	87.3	106.2	123.3
Net Increase in Current Assets	-9.0	-74.4	-157.6	-150.0
Net Increase in Current Liabilities	23.8	27.2	51.9	49.5
Others	-3.4	26.7	26.7	26.7
CF from Operating activities	**174.6**	**207.0**	**240.2**	**326.1**
Investments	0.5	0.0	0.0	0.0
(Purchase)/Sale of Fixed Assets	-179.2	-300.0	-250.0	-250.0
Others	-48.3	-1.5	-1.6	-1.6
CF from Investing activities	**-226.9**	**-301.5**	**-251.6**	**-251.6**
(inc)/Dec in Loan	-154.9	0.0	0.0	0.0
Dividend & Dividend tax	0.0	0.0	0.0	0.0
Other	190.9	123.6	-26.7	-26.7
CF from Financing activities	36.0	123.6	-26.7	-26.7
Net Cash Flow	**-16.3**	**29.0**	**-38.1**	**47.8**
Cash and Cash Equivalent	26.4	10.0	39.1	1.0
Cash	**10.0**	**39.1**	**1.0**	**48.8**
Free Cash Flow	**-4.6**	**-93.0**	**-9.8**	**76.1**

Source: Company, ICICI Direct Research

Exhibit 20: Balance Sheet ₹ crore

(Year-end March)	FY26	FY27E	FY28E	FY29E
Equity Capital	12.5	12.9	12.9	12.9
Reserve and Surplus	1,145.0	1,435.2	1,648.2	1,924.9
Total Shareholders' funds	1,157.5	1,448.0	1,661.1	1,937.7
Total Debt	391.0	391.0	391.0	391.0
Deferred Tax Liability	5.8	5.9	6.0	6.2
Long-Term Provisions	21.6	22.0	22.4	22.9
Other Non-Current Liabilities	5.8	5.9	6.0	6.1
Source of Funds	**1,581.7**	**1,872.9**	**2,086.6**	**2,363.9**
Gross Block - Fixed Assets	1,123.2	1,423.2	1,673.2	1,923.2
Accumulated Depreciation	38.8	126.1	232.2	355.5
Net Block	1,084.4	1,297.1	1,440.9	1,567.6
Capital WIP	64.5	64.5	64.5	64.5
Fixed Assets	1,148.9	1,361.6	1,505.4	1,632.1
Investments	35.9	35.9	35.9	35.9
Other non-Current Assets	110.4	112.7	114.9	117.2
Inventory	236.9	277.0	362.5	443.8
Debtors	197.6	231.1	302.4	370.2
Other Current Assets	41.0	41.8	42.7	43.5
Cash	10.0	39.1	1.0	48.8
Total Current Assets	485.5	589.0	708.5	906.3
Creditors	138.3	164.3	215.0	263.2
Provisions	3.6	3.7	3.8	3.9
Other Current Liabilities	57.2	58.4	59.5	60.7
Total Current Liabilities	199.2	226.4	278.3	327.8
Net Current Assets	286.3	362.6	430.2	578.5
Application of Funds	**1,581.6**	**1,872.8**	**2,086.5**	**2,363.8**

Source: Company, ICICI Direct Research

Exhibit 21: Ratio Analysis

(Year-end March)	FY26	FY27E	FY28E	FY29E
Per share data (₹)				
Reported EPS	17.1	21.8	33.1	43.1
Cash EPS	18.5	21.8	33.1	43.1
BV per share	180.1	225.4	258.5	301.6
Cash per Share	1.6	6.1	0.2	7.6
Dividend per share	0.0	0.0	0.0	0.0
Operating Ratios (%)				
Gross Profit Margins	63.7	68.9	68.8	67.8
EBITDA margins	27.4	28.3	32.1	33.3
PAT Margins	13.7	13.8	16.0	17.0
Cash Conversion Cycle	124.4	123.5	123.5	123.5
Asset Turnover	0.8	0.7	0.8	0.8
EBITDA conversion Rate	73.4	72.0	56.2	60.1
Return Ratios (%)				
RoE	10.3	9.7	12.8	14.3
RoCE	11.9	10.8	15.5	17.8
RoIC	12.2	11.3	15.9	18.6
Valuation Ratios (x)				
P/E	70.2	55.0	36.2	27.9
EV / EBITDA	34.0	28.0	19.0	14.8
EV / Net Sales	9.3	7.9	6.1	4.9
Market Cap / Sales	8.9	7.6	5.8	4.7
Price to Book Value	6.7	5.3	4.6	4.0
Solvency Ratios				
Debt / EBITDA	1.6	1.4	0.9	0.7
Debt / Equity	0.3	0.3	0.2	0.2
Current Ratio	2.4	2.4	2.5	2.6
Quick Ratio	**1.2**	**1.2**	**1.2**	**1.3**
Inventory days	99	99	99	99
Debtor days	83	83	83	83
Creditor days	58	59	59	59

Source: Company, ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according -to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%

Pankaj Pandey | Head – Research | pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk,
ICICI Securities Limited,
Third Floor, Brillanto House,
Road No 13, MIDC,
Andheri (East)
Mumbai – 400 093
research@icicidirect.com

ANALYST CERTIFICATION

I/We, Siddhant Khandekar, Inter CA; Shubh Mehta, MBA(Tech); Vedant Nilekar, MBA; Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Anoop Goyal

Contact number: 022-40701000 E-mail Address: complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Jeetu Jawrani Email address: headservicequality@icicidirect.com Contact Number: 18601231122
ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.
ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.
ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.
This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

ICICI Securities Limited has not used any Artificial Intelligence tools for preparation of this Research Report

SEBI Guidelines for Research Analyst (RA) requires all RAs to disclose terms and conditions pertaining to Research Services to all clients. Please go through the "Mandatory terms and conditions" and "Most Important Terms and Conditions".